“Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s617. doi:10.25251/gf6mb511.